摘要
钠-葡萄糖共转运蛋白2抑制剂(sodium-glucose cotransporter 2 inhibitor,SGLT2i)是一类新型口服降糖药物,其作用机制是抑制近端肾小管钠-葡萄糖重吸收,促进尿糖排泄,从而降低血糖浓度。多项研究表明SGLT2i的使用可以降低心血管不良事件发生的风险,改善T2DM合并心血管风险高危甚至心力衰竭患者的预后。本文通过对SGLT2i心血管系统的保护机制、循证医学证据和药物使用进展进行综述,探讨SGLT2i在心血管领域的临床应用。
Sodium-glucose cotransporter 2 inhibitor(SGLT2i)is a novel anti-diabetes drug with a unique mechanism of action through inhibiting renal glucose re-absorption and increasing uric glucose excretion.Several studies have shown that the use of SGLT2i can reduce the risk of adverse cardiovascular events and improve outcomes in patients with type 2 diabetes mellitus at high cardiovascular risk or even heart failure.This review summarizes the protective mechanisms,evidence-based medical evidence and drug use progress and discusses the clinical use of SGLT2i in cardiovascular field.
作者
舒冰
陈龙威
沈爱宗
SHU Bing;CHEN Long-wei;SHEN Ai-zong(Department of Pharmacy,the First Afiliated Hospital of University of Science and Technology of China/Anhui Provincial Hospital,Hefei 230001,China;Department of Pharmacy,The Second Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2023年第5期501-506,共6页
Chinese Journal of New Drugs
基金
合肥市“软科学”研究资助项目(2021026)。
